Pegfilgrastim compared to lenograstim after allogeneic peripheral blood stem-cell transplantation from unrelated donors

References

• Dekker A, Bulley S, Beyene J, Dupuis L L, Doyle J J, Sung L. Meta-analysis of randomized controlled trials of prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor after autologous and allogeneic stem cell transplantation. J Clin Oncol 2006; 24: 5207–5215
   PubMed Web of Science ®Google Scholar
• Weaver C H, Schwartzberg L S, Hainsworth J, Greco F A, Li W, Buckner C D, et al. Treatment-related mortality in 1000 consecutive patients receiving high-dose chemotherapy and peripheral blood progenitor cell transplantation in community cancer centers. Bone Marrow Transplant 1997; 19: 671–678
   PubMed Web of Science ®Google Scholar
• Sung L, Nathan P C, Alibhai S M, Tomlinson G A, Beyene J. Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. Ann Intern Med 2007; 147: 400–411
   PubMed Web of Science ®Google Scholar
• Klumpp T R, Mangan K F, Goldberg S L, Pearlman E S, Macdonald J S. Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial. J Clin Oncol 1995; 13: 1323–1327
   PubMed Web of Science ®Google Scholar
• Hornedo J, Sola C, Solano C, Lopez J J, Alonso S, Lluch A, et al. The role of granulocyte colony-stimulating factor (G-CSF) in the post-transplant period. Bone Marrow Transplant 2002; 29: 737–743
   PubMed Web of Science ®Google Scholar
• Spitzer G, Adkins D R, Spencer V, Dunphy F R, Petruska P J, Velasquez W S, et al. Randomized study of growth factors post-peripheral-blood stem-cell transplant: neutrophil recovery is improved with modest clinical benefit. J Clin Oncol 1994; 12: 661–670
   PubMed Web of Science ®Google Scholar
• Dunn C J, Goa K L. Lenograstim: an update of its pharmacological properties and use in chemotherapy-induced neutropenia and related clinical settings. Drugs 2000; 59: 681–717
   PubMed Web of Science ®Google Scholar
• Schmitz N, Ljungman P, Cordonnier C, Kempf C, Linkesch W, Alegre A, et al. Lenograstim after autologous peripheral blood progenitor cell transplantation: results of a double-blind, randomized trial. Bone Marrow Transplant 2004; 34: 955–962
   PubMed Web of Science ®Google Scholar
• Suh C, Kim H J, Kim S H, Kim S, Lee S J, Lee Y S, et al. Low-dose lenograstim to enhance engraftment after autologous stem cell transplantation: a prospective randomized evaluation of two different fixed doses. Transfusion 2004; 44: 533–538
   PubMed Web of Science ®Google Scholar
• Urbano-Ispizua A, Solano C, Brunet S, Hernandez F, Sanz G, Alegre A, et al. Allogeneic peripheral blood progenitor cell transplantation: analysis of short-term engraftment and acute GVHD incidence in 33 cases. allo-PBPCT Spanish Group. Bone Marrow Transplant 1996; 18: 35–40
   PubMed Web of Science ®Google Scholar
• Vanstraelen G, Frere P, Ngirabacu M C, Willems E, Fillet G, Beguin Y. Pegfilgrastim compared with Filgrastim after autologous hematopoietic peripheral blood stem cell transplantation. Exp Hematol 2006; 34: 382–388
   PubMed Web of Science ®Google Scholar
• Delgado C, Francis G E, Fisher D. The uses and properties of PEG-linked proteins. Crit Rev Ther Drug Carrier Syst 1992; 9: 249–304
   PubMed Web of Science ®Google Scholar
• Molineux G. Pegfilgrastim: using pegylation technology to improve neutropenia support in cancer patients. Anticancer Drugs 2003; 14: 259–264
   PubMed Web of Science ®Google Scholar
• Molineux G, Kinstler O, Briddell B, Hartley C, McElroy P, Kerzic P, et al. A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Exp Hematol 1999; 27: 1724–1734
   PubMed Web of Science ®Google Scholar
• Morstyn G, Foote M A, Walker T, Molineux G. Filgrastim (r-metHuG-CSF) in the 21st century: SD/01. Acta Haematol 2001; 105: 151–155
   PubMed Web of Science ®Google Scholar
• Lord B I, Woolford L B, Molineux G. Kinetics of neutrophil production in normal and neutropenic animals during the response to filgrastim (r-metHu G-CSF) or filgrastim SD/01 (PEG-r-metHu G-CSF). Clin Cancer Res 2001; 7: 2085–2090
   PubMed Web of Science ®Google Scholar
• Vose J M, Crump M, Lazarus H, Emmanouilides C, Schenkein D, Moore J, et al. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol 2003; 21: 514–519
   PubMed Web of Science ®Google Scholar
• Cheung E, Cozenza M, Lopez O. Modeling of r-metHUG-CSF-SD/01 mediated granulopoiesis in normal animals, with mathematical extrapolation to neutropenic settings. Blood 1998; 92: 379a, ASH annual meeting abstracts
   Google Scholar
• Farese A M, Yang B B, Roskos L, Stead R B, MacVittie T J. Pegfilgrastim, a sustained-duration form of filgrastim, significantly improves neutrophil recovery after autologous marrow transplantation in rhesus macaques. Bone Marrow Transplant 2003; 32: 399–404
   PubMed Web of Science ®Google Scholar
• Lee S M, Radford J A, Dobson L, Huq T, Ryder W D, Pettengell R, et al. Recombinant human granulocyte colony-stimulating factor (filgrastim) following high-dose chemotherapy and peripheral blood progenitor cell rescue in high-grade non-Hodgkin's lymphoma: clinical benefits at no extra cost. Br J Cancer 1998; 77: 1294–1299
   PubMed Web of Science ®Google Scholar
• Staber P B, Holub R, Linkesch W, Schmidt H, Neumeister P. Fixed-dose single administration of Pegfilgrastim vs daily Filgrastim in patients with haematological malignancies undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2005; 35: 889–893
   PubMed Web of Science ®Google Scholar
• Jagasia M H, Greer J P, Morgan D S, Mineishi S, Kassim A A, Ruffner K L, et al. Pegfilgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplant: phase II study. Bone Marrow Transplant 2005; 35: 1165–1169
   PubMed Web of Science ®Google Scholar
• Lyman G H. Pegfilgrastim: a granulocyte colony-stimulating factor with sustained duration of action. Expert Opin Biol Ther 2005; 5: 1635–1646
   PubMed Web of Science ®Google Scholar
• De la Rubia J. Pegfilgrastim as adjunct to chemotherapy to mobilize hematopoietic stem cells. Haematologica 2005; 90: 150
   PubMedGoogle Scholar
• Fruehauf S, Klaus J, Huesing J, Veldwijk M R, Buss E C, Topaly J, et al. Efficient mobilization of peripheral blood stem cells following CAD chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplant 2007; 39: 743–750
   PubMed Web of Science ®Google Scholar
• Nosari A, Cairoli R, Ciapanna D, Gargantini L, Intropido L, Barate C, et al. Efficacy of single dose pegfilgrastim in enhancing the mobilization of CD34+ peripheral blood stem cells in aggressive lymphoma patients treated with cisplatin-aracytin-containing regimens. Bone Marrow Transplant 2006; 38: 413–416
   PubMed Web of Science ®Google Scholar
• Malerba L, Mele A, Leopardi G, Stramigioli S, Politi P, Visani G. Pegfilgrastim effectively mobilizes PBSC in a poor mobilizer multiple myeloma patient. Eur J Haematol 2006; 76: 436–439
   PubMed Web of Science ®Google Scholar
• Bruns I, Steidl U, Kronenwett R, Fenk R, Graef T, Rohr U P, et al. A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma. Transfusion 2006; 46: 180–185
   PubMed Web of Science ®Google Scholar
• Kroschinsky F, Holig K, Poppe-Thiede K, Zimmer K, Ordemann R, Blechschmidt M, et al. Single-dose pegfilgrastim for the mobilization of allogeneic CD34+ peripheral blood progenitor cells in healthy family and unrelated donors. Haematologica 2005; 90: 1665–1671
   PubMed Web of Science ®Google Scholar
• Fenk R, Hieronimus N, Steidl U, Bruns I, Graef T, Zohren F, et al. Sustained G-CSF plasma levels following administration of pegfilgrastim fasten neutrophil reconstitution after high-dose chemotherapy and autologous blood stem cell transplantation in patients with multiple myeloma. Exp Hematol 2006; 34: 1296–1302
   PubMed Web of Science ®Google Scholar
• Kroschinsky F, Holig K, Platzbecker U, Poppe-Thiede K, Ordemann R, Blechschmidt M, et al. Efficacy of single-dose pegfilgrastim after chemotherapy for the mobilization of autologous peripheral blood stem cells in patients with malignant lymphoma or multiple myeloma. Transfusion 2006; 46: 1417–1423
   PubMed Web of Science ®Google Scholar
• Steidl U, Fenk R, Bruns I, Neumann F, Kondakci M, Hoyer B, et al. Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplant 2005; 35: 33–36
   PubMed Web of Science ®Google Scholar
• Green M D, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003; 14: 29–35
   PubMed Web of Science ®Google Scholar
• Przepiorka D, Weisdorf D, Martin P, Klingemann H G, Beatty P, Hows J, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825–828
   PubMed Web of Science ®Google Scholar
• Shulman H M, Sullivan K M, Weiden P L, McDonald G B, Striker G E, Sale G E, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204–217
   PubMed Web of Science ®Google Scholar
• Welte K, Gabrilove J, Bronchud M H, Platzer E, Morstyn G. Filgrastim (r-metHuG-CSF): the first 10 years. Blood 1996; 88: 1907–1929
   PubMed Web of Science ®Google Scholar
• Martino M, Pratico G, Messina G, Irrera G, Massara G, Console G, Iacopino. Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients. Eur J Haematol 2006; 77: 410–415
   PubMed Web of Science ®Google Scholar
• Musto P, Scalzulli P R, Terruzzi E, Rossini F, Iacopino P, Messina G, et al. Peg-filgrastim versus filgrastim aftzer autologous stem cell transplantation: case control study in patients with multiple myeloma and review of the literature. Leuk Res 2007; 31: 1487–1493
   PubMed Web of Science ®Google Scholar